Imperial College London
Alternate

Professor Neil Poulter

Faculty of Medicine, School of Public Health

Professor of Preventive Cardiovascular Medicine.
 
 
 
//

Contact

 

+44 (0)20 7594 3446n.poulter

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

55Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Verma:2018:10.1161/CIRCULATIONAHA.118.034516,
author = {Verma, S and Poulter, NR and Bhatt, DL and Bain, SC and Buse, JB and Leiter, LA and Nauck, MA and Pratley, RE and Zinman, B and Ørsted, DD and Monk, Fries T and Rasmussen, S and Marso, SP},
doi = {10.1161/CIRCULATIONAHA.118.034516},
journal = {Circulation},
pages = {2884--2894},
title = {Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke.},
url = {http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034516},
volume = {138},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes). In a post hoc analysis, we evaluated the efficacy of liraglutide in those with and without a history of myocardial infarction (MI) and/or stroke. METHODS: LEADER was a randomized trial of liraglutide (1.8 mg or maximum tolerated dose) versus placebo in 9340 patients with type 2 diabetes mellitus and high cardiovascular risk, with a median follow-up of 3.8 years. The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke (major adverse cardiovascular events). Risk groups in this post hoc analysis were defined by history of MI/stroke, established atherosclerotic cardiovascular disease without MI/stroke, or cardiovascular risk factors alone. RESULTS: Of the 9340 patients, 3692 (39.5%) had a history of MI/stroke, 3083 (33.0%) had established atherosclerotic cardiovascular disease without MI/stroke, and 2565 (27.5%) had risk factors alone. Major adverse cardiovascular events occurred in 18.8% of patients with a history of MI/stroke (incidence rate, 5.0 per 100 patient-years), 11.6% of patients with established atherosclerotic cardiovascular disease without MI/stroke (incidence rate, 3.0 per 100 patient-years), and 9.8% of patients with cardiovascular risk factors alone (incidence rate, 2.6 per 100 patient-years). Liraglutide reduced major adverse cardiovascular events in patients with a history of MI/stroke (322 of 1865 [17.3%] versus 372 of 1827 patients [20.4%]; hazard ratio, 0.85; 95% CI, 0.73-0.99) and in those with established atherosclerotic cardiovascular disease without MI/stroke (158 of 1538 [10.3%] versus 199 of 1545 patients [12.9%]; hazard ratio, 0.76; 95% CI, 0.62-0.94) compared with placebo. In patients with risk factors alone, the hazard ratio for liraglutide versus placebo was 1.08 (95% CI, 0.84-1.3
AU  - Verma,S
AU  - Poulter,NR
AU  - Bhatt,DL
AU  - Bain,SC
AU  - Buse,JB
AU  - Leiter,LA
AU  - Nauck,MA
AU  - Pratley,RE
AU  - Zinman,B
AU  - Ørsted,DD
AU  - Monk,Fries T
AU  - Rasmussen,S
AU  - Marso,SP
DO  - 10.1161/CIRCULATIONAHA.118.034516
EP  - 2894
PY  - 2018///
SN  - 0009-7322
SP  - 2884
TI  - Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke.
T2  - Circulation
UR  - http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034516
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30566004
UR  - http://hdl.handle.net/10044/1/90481
VL  - 138
ER  -
Download